AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast cancer
Description: Participants will view messages about the risk of breast cancer from alcohol consumption.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cancer (generic, not site-specific)
Description: Participants will view messages about the risk of cancer (not site-specific) from alcohol consumption.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Addiction and neurological changes
Description: Participants will view messages about the risk of addiction and neurological changes from alcohol consumption.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypertension
Description: Participants will view messages about the risk of hypertension from alcohol consumption.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Liver damage
Description: Participants will view messages about the risk of liver damage from alcohol consumption.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harm to fetus
Description: Participants will view messages about the risk of harm to a fetus from alcohol consumption during pregnancy.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dementia
Description: Participants will view messages about the risk of dementia from alcohol consumption.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impaired sleep
Description: Participants will view messages about the risk of impaired sleep from alcohol consumption.
Study NCT06214156 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011
Description: T3011 will be given intratumorally， Q2W；
Study NCT04019119 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital intervention
Description: The information group will receive through a mobile application tips to reduce sedentary lifestyle and promote healthy living habits.
Study NCT04928638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual educational intervention
Description: Educational intervention about the disease, the use of medication and the context of pandemic
Study NCT04928638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written educational intervention
Description: Educational intervention about the disease, the use of medication and the context of pandemic
Study NCT05777278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Savolitinib (300mg or 200mg according to safety run-in recommendation, p.o., BID)
Study NCT05777278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (60 mg/m2, ivgtt, q3w)
Study NCT04823897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCI-001
Description: Dose Escalation Phase: CCI-001 will be administered by intravenous infusion starting at 1.2mg per square metre of body surface area in the first cohort. The dose will be escalated sequentially in subsequent cohorts. The degree of dose escalation between subsequent cohorts will depend on tolerability, as judged by NCI-CTCAE grading. Once the maximum tolerated dose is determined this phase will be complete.~Dose Expansion Phase: cohorts of patients with the following tumour types will be enrolled: transitional cell bladder cancer, pancreaticobiliary adenocarcinomas, gynecologic cancers (ovarian, cervical, endometrial), and lung adenocarcinoma. These patients will be treated at the dose determined in the dose escalation phase.
Study NCT05056376 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Diabetes Prevention Program (dDPP)
Description: The Sweetch app is a hyper-personalized mobile digital coach that provides users with tailored recommendations to promote healthy lifestyle behaviors (150 minutes per week of physical activity, weight reduction, and healthy eating habits) to reduce the risk of type 2 diabetes.~The Sweetch app uses self-tracking and multiple evidence-based persuasive eCoaching strategies. The Sweetch artificial intelligence algorithm delivers just-in-time support and/or adapt recommendations based on the user's response. For example, push notifications will be sent when the algorithm detects that the user is potentially available and able to act upon the recommendation, based on various parameters including location, previous response, calendar availability, and weather, etc.
Study NCT05056376 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Human Coach-based Diabetes Prevention Program (hDPP)
Description: The Human Coach-Based Diabetes Prevention Program will consist of a CDC recognized lifestyle change program. Participants will attend a total of 16 weekly sessions during months 1 to 6 and 6 sessions during months 7 to 12. These group sessions may be delivered in-person at the local program or remotely using video conferencing. During these sessions, participants will receive information about lifestyle change behaviors focusing on weight loss, physical activity, and nutrition from a trained lifestyle coach.
Study NCT05048238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib
Description: 10 participants with Cutaneous lupus erythematosus (CLE). Consenting individuals meeting all entry criteria will undergo 25 days of treatment with tofacitinib (11 mg orally (PO) daily) with evaluation of UVB-mediated cutaneous apoptosis
Study NCT06561854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: ICARIA schema :~40mg (20mg for ≥75yr) on day 1, 8, 15, 22 of each cycle plus~IKEMA schema :~20 mg on day 1-2, day 8-9, day 15-16 and day 22-23 of each cycle~For subjects older than 75 years or underweight (BMI \<18.5), the dexamethasone dose may be administered at a total dose of 20 mg weekly.~In both schema (ICARIA or IKEMA), dexamethasone will be administrated up to 2 cycle (Arm 1) or until disease progression (Arm2)
Study NCT06235892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACROLIMUS
Description: TACROLIMUS 2-3.5 ng/ml
Study NCT05676489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [F-18]MeFAMP PET
Description: Study participants will receive the fluorine-18 labeled system A amino acid transport substrate, (R)-3-\[F-18\]fluoro-2-methyl-2-(methylamino)propanoic acid (\[F-18\]MeFAMP), for positron emission tomography (PET). Participants in Cohorts 1 and 2 will receive a single administration of the study drug. Participants in cohort 3 will receive 2 administrations of the study drug, once before standard of care radiation therapy for brain metastases and once after.
Study NCT03807973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [Zr-89]Oxine-labeled leukocytes PET/MRI
Description: All study participants will undergo an investigational imaging study using autologous \[Zr-89\]-labeled leukocytes and brain PET/MRI. Participants will undergo a venous blood draw, and the leukocytes in the blood sample will be isolated for labeling using \[Zr-89\]oxine. The labeled leukocytes (7.4- 18.5 megabecquerel (MBq), 200-500 uCi) will be re-injected into the participant followed by brain PET/MRI at 24-48 hours after injection. Participants will be asked to have a second brain imaging study 3-6 days after this injection, but this second imaging study is optional.
Study NCT05421897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab with Chemotherapy
Description: Rapid infusion of dinutuximab in 4 hours or less
Study NCT05034783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-HBED-CC-exendin-4
Description: Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) \[68Ga\]Ga-HBED-CC-exendin-4. Tracer doses of \[68Ga\]Ga-HBED-CC-exendin-4 will be used to image lesions of insulinoma by PET/CT.
Study NCT05034783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-exendin-4
Description: Intravenous injection of one dosage of 74-111 MBq (2-3 mCi) \[68Ga\]Ga-NOTA-exendin-4. Tracer doses of \[68Ga\]Ga-NOTA-exendin-4 will be used to image lesions of insulinoma by PET/CT.
Study NCT05462587 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVTX-803 (L-Fucose)
Description: L-fucose crystalline powder
Study NCT04933097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfet2®
Description: Conducting a day hospitalization including analyses:~1. Quantitative muscular analysis by measuring the DEXA of the whole body, the reference method for measuring body compartments and allowing the diagnosis of sarcopenia (IMMA\<7 in men and 5.5 in women)~2. Qualitative muscular analysis:~   * isokinetic measurement of muscular strength carried out on 3 muscle groups using a manual measurement sensor such as Microfet2 ® : quadriceps, triceps brachii, biceps~  * measurement of grip strength using Jamar® equipment validated as recommended by the EWGSOP~  * a walking test to assess the functional impact of sarcopenia and its severity
Study NCT06593665 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Inrathecal Morphine
Description: Intrathecal preservative free morphine (duramorph) 200 mcg with 7.5mg of hyperbaric bupivacaine placed by a spinal needle prior to induction of general anesthesia (n=71)
Study NCT06593665 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Methadone
Description: Intravenous methadone dosed at 0.2 mg/kg Ideal Body weight up to a maximum dose of 20mg, rounded to the nearest milligram, for all patients given during the induction of general anesthesia (n=71)
Study NCT05313191 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pencil Beam Scanning Proton Therapy
Description: Use of Pencil Beam Scanning Proton Therapy compared with historical outcomes using photon therapy for the reirradiation of recurrent or new primary malignancies
Study NCT06381492 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: MRI using DTI technology
Study NCT06381492 — intervention group
Intervention type: DEVICE
Intervention: Ultrasound (US)
Description: Standard US
Study NCT06381492 — intervention group
Intervention type: DEVICE
Intervention: Neuromuscular electric stimulation (NMES)
Description: Standard NMES
Study NCT06476834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study NCT06638632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Patients with dementia and care partners will receive an iteration of the decision aid and provide feedback.
Study NCT06670521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 50 mg methylprednisolone IV every 6 hours for 4 doses to reduce laryngeal edema
Study NCT06670521 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal Saline placebo IV every 6 hours for 4 doses
Study NCT06671665 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: calcium supplementation
Description: Patients in both groups received calcium supplementation in the form of tablets that contain 665 mg calcium citrate. Citrate is easily assimilated and metabolized which provides the maximum benefit of the formula. Dosage: one tablet daily.
Study NCT06671665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium supplementation
Description: Patients in both groups received calcium supplementation in the form of tablets that contain 665 mg calcium citrate. Citrate is easily assimilated and metabolized which provides the maximum benefit of the formula. Dosage: one tablet daily.
Study NCT05898269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tidal volume challenge
Description: Increase in tidal volume set on the ventilator from 6 ml.kg-1 of predicted body weight, to 8 ml.kg-1 for 60 seconds.~Evaluator: difference in the pulse pressure variation measured at 6 ml.kg-1 and at 8 ml.kg-1.
Study NCT05898269 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Fluid bolus (reference diagnostic method)
Description: After the 4 tests, the patient will receive a 500-ml fluid bolus of crystalloids in less than 15 minutes.~Evaluator (reference method): cardiac index measured by transpulmonary thermodilution before and immediately after the fluid bolus. Patients with a relative change in cardiac index > 15% will be identified as being fluid responders, and the others as non-responders.
Study NCT06671665 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Manual therapy treatment will be in the form of craniosacral techniques and visceral manipulation techniques for 8 sessions in 12 weeks. Sessions will be divided into one session per week for the first 4 weeks then one session every two week for the next 8 weeks. Each session lasts for 45 minutes.
Study NCT05681442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous pivotal βL-AB
Description: continuous pivotal βL-AB
Study NCT05681442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intermittent pivotal βL-AB
Description: intermittent pivotal βL-AB (IID = control group)
Study NCT05681442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG infusion most 1 dose
Description: AG infusion most 1 dose (AMT group )
Study NCT05681442 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG infusion for 5 days
Description: AG infusion for 5 days (ACT Group)
Study NCT06393998 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Breathing with CO2 during daytime and night at high altitude
Description: Subjects wear the mask connecting to low dose CO2 supplied by a novel device during daytime and sleep dependent on the randomization once arriving high altitude.
Study NCT06393998 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sleep and doing exercise test under inhalation of air
Description: Subjects wear the mask connecting to air supplied by the novel device during daytime and sleep dependent on the randomization once arriving high altitude.
Study NCT05658341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADA
Description: The 12-weeks program will include one-hour in adapted physical activity (APA), and a discussion on relaxation techniques and the undertaking of deep breathing exercises (making them APA+ sessions). A series of minute for nutrition short information sheets will be distributed at the end of each session.~Two workshops on living better after breast cancer will also be offered: one on general mobility and the other on daily nutrition.~Moreover, women will be asked to set personal challenges as a method of motivational reinforcement, and will also be called for motivational check-ins at least 3 times. Follow-up calls will allow for further individualization, motivation, and the reception of participants' concerns or remarks.~Further, participants in the intervention group will have access to a dedicated internet space containing several documents and videos on topics of concern to patients during the post-treatment phase.
Study NCT05658341 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants in the control group will be offered weekly APA sessions for 12 weeks, these sessions are based on current practices within the Siel Bleu organization. Sessions' content is adapted to people who have been treated for (all types) cancer and are based on current recommendations.~These sessions are commonly organized by Siel Bleu in hospitals, community groups or local committees of the national league against cancer organization.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Drinking guidelines
Description: Participants will view messages about guidelines for alcohol consumption.
Study NCT05843448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-L1/IDO Peptide Vaccine
Description: Given SC
Study NCT05843448 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT04802954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video acquisition
Description: One to three video acquisitions of 10 seconds will be carried out via the intercostal route. Data acquisition will be standardized according to a mandatory protocol and previously recorded in each ultrasound machine (cross shots, harmonic, filter, depth, focal length, mechanical index, etc.).
Study NCT06542588 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HLX07(anti EGFR antibody) and Serplulimab(anti PD-1 antibody)
Description: Short course radiotherapy sequential HLX07, Serplulimab and chemotherapy
Study NCT06195332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open TAR
Description: Participants will undergo open TAR repair according to the assigned treatment arm.
Study NCT06195332 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic TAR
Description: Participants will undergo endoscopic TAR repair according to the assigned treatment arm.
Study NCT05780723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment group: Rectal instillation of QHQYP
Description: QHQYP is decocted in water, with a dose of 100ml each time, and rectal drip before going to bed, once a night, for 8 weeks.
Study NCT05780723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group: Mesalazine enema treatment
Description: Mesalazine enema, 4g/tube, 1 tube each time, enema before bed, once a night, a total of 8 weeks of continuous treatment.
Study NCT04658342 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Videofluoroscopic imaging (VFSS) with high-resolution manometry (HRM)
Description: The Videofluoroscopic Imaging (VFSS) is done by inserting a small catheter into the nose and down the throat. The catheter is approximately .4 millimeters in diameter. A trained speech-language pathologist will insert the catheter after applying numbing medicine, or topical anesthetic, inside the nose.~The high-resolution manometry (HRM) is a swallowing pressure test done at the same time as the VFSS. The HRM will measure how strong the throat muscle squeeze the liquids and foods that a person swallows.~The VFSS and HRM will occur about one month after surgery and three months after the completion of the radiation treatment.
Study NCT05109494 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Fractionated
Description: 50 Gy in 25 fractions will be prescribed to cover 95% of the planning tumor volume (PTV). More than 99% of the PTV should receive > 97% of the prescribed dose. For dose homogeneity, no more than 20% of the PTV will receive ≥ 110% prescription dose.
Study NCT05109494 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated
Description: 27.5 Gy in 5 fractions will be prescribed to cover 95% of the PTV. More than 99% of the PTV should receive > 97% of the prescribed dose
Study NCT06056219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: 30 minutes' mirror therapy included movements of forearm, wrist, fingers and thumb, as well as a tendon gliding exercise of less-affected upper extremity using a mirror box
Study NCT06056219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality-based mirror therapy with rhythmic skill training
Description: 30 minutes' virtual reality-based mirror therapy with rhythmic skill training included musical exercises involving virtual drums playing with less-affected upper extremity, and synchronized virtual drums playing and singing activity
Study NCT06056219 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task-oriented training
Description: 20 minutes' motor training targeted to goals that are relevant to the functional needs of the patient
Study NCT06056219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented training
Description: 20 minutes' motor training targeted to goals that are relevant to the functional needs of the patient
Study NCT04974099 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RoadMAB
Description: The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.
Study NCT04974099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Precision dosing with a dashboard
Description: The trial is testing whether precision dosing can more reliably achieve the targeted trough concentrations compared to standard dosing
Study NCT06675981 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Real Acupuncture
Description: Patients received 6 sessions of acupuncture (three sessions per week or every other day) for two consecutive weeks
Study NCT06675981 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Non-acupuncture at real-acupoint
Description: The acupuncture simulation device will be used to perform acupuncture at the same acupoints as those of the real acupuncture group.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Participants will view neutral messages unrelated to the harms of alcohol consumption.
Study NCT06159647 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Road injuries
Description: Participants will view messages about the risk of road injuries from alcohol consumption.
Study NCT06004388 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Click Digital Therapeutic
Description: Evaluate the efficacy and safety of prescription mobile applications that provide an interactive, software-based intervention for the preventative treatment of episodic migraine in late adults and adolescents receiving Calcitonin Gene-Related Peptide (CGRP) Inhibitor Therapy